TCGA-78-7161-01A-11R-2039-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.300
- PANCREAS_BETA_CELLS+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.190
- COAGULATION+0.180
- UV_RESPONSE_DN+0.060
- HEDGEHOG_SIGNALING+0.040
- MYOGENESIS+0.020
- ESTROGEN_RESPONSE_EARLY+0.000
- ANDROGEN_RESPONSE-0.030
Top 10 suppressed
- E2F_TARGETS-0.590
- ALLOGRAFT_REJECTION-0.520
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V2-0.460
- MTORC1_SIGNALING-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- MYC_TARGETS_V1-0.410
- DNA_REPAIR-0.370
- IL6_JAK_STAT3_SIGNALING-0.350
- OXIDATIVE_PHOSPHORYLATION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e3d71c3f-4e56-45fa-be88-2cf444b70a5c | — | — | 0.908 |
| 2 | SRR10900003 | — | — | 0.895 |
| 3 | C3L-02165 | — | cohortA2 | 0.889 |
| 4 | C3N-03921 | — | cohortA1 | 0.877 |
| 5 | TCGA-B6-A0X7-01A-11R-A10J-07 | — | A | 0.872 |
| 6 | fe036511-fe82-467c-9c6e-59bfb8b0a329 | — | — | 0.869 |
| 7 | SRR8518225 | — | B | 0.868 |
| 8 | C3N-01409 | — | cohortA1 | 0.865 |
| 9 | SRR25617855 | — | A | 0.857 |
| 10 | b4f1e5a5-061a-498b-aadc-bd568f0e4f87 | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |